Welcome to our dedicated page for Avanos Medical SEC filings (Ticker: AVNS), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
From post-surgical cold-compression pumps to neonatal feeding tubes, Avanos Medical’s product line touches some of healthcare’s most sensitive moments. Investors digging into how the company manages regulatory risk, R&D spending, or global recall exposure know the answers live inside its SEC disclosures—yet those files can exceed 300 pages of technical detail.
Stock Titan’s AI engine turns every Avanos Medical quarterly earnings report 10-Q filing and annual report 10-K into plain-language highlights. Need Avanos Medical insider trading Form 4 transactions before the market opens? Our real-time feed surfaces Avanos Medical Form 4 insider transactions real-time and flags patterns in executive stock transactions Form 4. Curious about supply-chain updates or FDA clearances? We tag each Avanos Medical 8-K material events explained so you see the headline without reading footnotes. Even the dense Avanos Medical proxy statement executive compensation is broken down into concise tables.
Here’s how specialists, portfolio managers, and compliance teams use the page:
- Compare non-opioid therapy revenue across periods with Avanos Medical earnings report filing analysis.
- Set alerts for understanding Avanos Medical SEC documents with AI to spot margin-moving disclosures.
- Download red-lined versions of Avanos Medical SEC filings explained simply for faster peer review.
Every document—10-K, 10-Q, 8-K, S-8, Section 16 forms—is captured seconds after EDGAR posts, then summarized by our natural-language model. Historical search lets you trace clinical-trial milestones back through years of Avanos Medical annual report 10-K simplified narratives. Whether you follow digestive-health devices, pain-management trends, or simply want compliance-ready data, Stock Titan delivers the entire picture in one place, saving hours per filing and letting you focus on the investment decision itself.
On 06/30/2025, The Vanguard Group filed Amendment No. 10 to Schedule 13G reporting its ownership of Chemours Company (CC) common stock.
- Shares beneficially owned: 17,663,980
- Ownership percentage: 11.8 % of outstanding shares
- Voting power: 0 sole; 181,238 shared
- Dispositive power: 17,324,381 sole; 339,599 shared
Vanguard qualifies as an investment adviser under Rule 13d-1(b)(1)(ii)(E). The firm states the position is held in the ordinary course of business and not to influence control. Clients of Vanguard retain rights to dividends and sale proceeds.
Crossing the 10 % threshold makes Vanguard a significant institutional holder, potentially enhancing liquidity and investor confidence, although its near-zero sole voting power limits direct governance influence.
FAQ
What is the current stock price of Avanos Medical (AVNS)?
What is the market cap of Avanos Medical (AVNS)?
What does Avanos Medical do?
What are the core business areas of Avanos Medical?
How does Avanos Medical maintain its competitive edge in the industry?
What technologies or therapies is Avanos Medical known for?
In which markets does Avanos Medical operate?
How does Avanos Medical address patient safety and recovery?
What is the significance of the company’s transformation process?
How do Avanos Medical's products contribute to reducing opioid usage?
